Literature DB >> 30509942

In Vitro Activity of Omadacycline against Chlamydia pneumoniae.

Stephan A Kohlhoff1, Natalia Huerta2, Margaret R Hammerschlag2.   

Abstract

The in vitro activities of omadacycline, azithromycin, doxycycline, moxifloxacin, and levofloxacin were tested against 15 isolates of Chlamydia pneumoniae The minimum inhibitory concentration at which 90% of the isolates of C. pneumoniae were inhibited by omadacycline was 0.25 μg/ml (range, 0.03 to 0.5 μg/ml).
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Chlamydia pneumoniaezzm321990; omadacycline; tetracyclines

Mesh：

Substances：

Year:  2019        PMID： 30509942      PMCID： PMC6355552          DOI： 10.1128/AAC.01907-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae.

Authors:  P M Roblin; W Dumornay; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

2.  In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  Stephan A Kohlhoff; Michael D Huband; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

Review 3.  Treatment of Chlamydial infections: 2014 update.

Authors:  Stephan A Kohlhoff; Margaret R Hammerschlag
Journal:  Expert Opin Pharmacother       Date:  2015-02       Impact factor: 3.889

4.  In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Yang Liu; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

5.  Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014).

Authors:  M A Pfaller; P R Rhomberg; M D Huband; R K Flamm
Journal:  Diagn Microbiol Infect Dis       Date:  2017-10-19       Impact factor: 2.803

6.  Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.

Authors:  Mark H Gotfried; Karolyn Horn; Lynne Garrity-Ryan; Stephen Villano; Evan Tzanis; Surya Chitra; Amy Manley; S Ken Tanaka; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191
  6 in total
  5 in total

1.  In Vitro Activity of Levonadifloxacin (WCK 771) against Chlamydia pneumoniae.

Authors:  Stephan Kohlhoff; Natalia Huerta; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 2.  Clinical Utility of Lefamulin: If Not Now, When?

Authors:  Nicholas J Mercuro; Michael P Veve
Journal:  Curr Infect Dis Rep       Date:  2020-07-09       Impact factor: 3.725

3.  Microbiology and Preclinical Review of Omadacycline.

Authors:  James A Karlowsky; Judith Steenbergen; George G Zhanel
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

4.  Omadacycline for the Treatment of Severe Chlamydia psittaci Pneumonia Complicated with Multiple Organ Failure: A Case Report.

Authors:  Changquan Fang; Limin Xu; Jiarong Tan; Hongyi Tan; Junhong Lin; Ziwen Zhao
Journal:  Infect Drug Resist       Date:  2022-10-04       Impact factor: 4.177

5.  The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials.

Authors:  Shao-Huan Lan; Shen-Peng Chang; Chih-Cheng Lai; Li-Chin Lu; Chien-Ming Chao
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.